FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Mckesson Corporation

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target to $860 from $1,080, 19.4x our FY 27 EPS estimate (up $0.11 to $44.24; FY 28 estimate begins at $50.19), a above peers and MCK's three-year forward average of 18.6x, supported by a stronger margin profile and faster near-term EPS and dividend growth expectations within a favorable environment for pharma distributors, in our view. Looking ahead to FY 27, we expect broad-based growth across core pharma distribution, oncology and multispecialty, and Rx Technology, with more modest growth in Medical-Surgical, supporting overall sales growth near 7%, following 12% growth in FY 26. We attribute the sales growth slowdown to difficult comparisons as well as lower branded drug pricing as certain Inflation Reduction Act provisions take effect. Oncology and multispecialty should produce the strongest profitability growth during FY 27, in our view, followed by the Rx Technology business and core pharma distribution, driving overall adjusted EBIT growth near 9%.

Related Articles

Oil & Energy

Crude Benchmarks Post Weekly Slump Amid Hormuz Escalation, Peace Deal Doubts

Global oil benchmarks ended the week in negative territory on Friday, as a volatile mix of military escalation in the Strait of Hormuz and tentative hopes for a diplomatic breakthrough kept markets on edge.West Texas Intermediate settled at $94.68/bbl, down from $102.50/bbl the previous week, while Brent closed at $100.14/bbl, compared with $109.20/bbl a week earlier.WTI registered a weekly loss of 6.4%, while Brent declined 7.42%.Despite late-week price spikes driven by renewed fire exchanges, both benchmarks still ended the week lower, weighed down by earlier optimism that a 14-point US-Iran peace memorandum could eventually reopen global shipping lanes.The week began with the US military launching "Project Freedom" to escort commercial vessels through the blockaded Strait of Hormuz.This move triggered immediate Iranian missile and drone strikes against UAE infrastructure and transit vessels, with Tehran claiming the operation violated restricted zones.The Strait of Hormuz remains effectively closed, with renewed clashes between US and Iranian forces reducing the prospect of a near-term reopening, Saxo Bank strategists said.On Friday, the UAE Defense Ministry said Friday its air defenses engaged two ballistic missiles and three drones launched from Iran, the third time this week that it has fired on the UAE.While the US subsequently drafted a UN Security Council resolution to safeguard navigation, President Donald Trump's mid-week announcement of "great progress" on a peace deal briefly calmed the market.Prices retreated as Washington paused its escort missions to allow Tehran time to review a one-page memorandum of understanding intended to end the conflict.However, sentiment was later challenged by a tightening supply picture in the US.The Energy Information Administration reported a 2.3-million-barrel drawdown in US crude inventories, bringing stocks to 457.2 mmbbls.Market analysts noted that US refineries are increasingly reliant on domestic stocks to offset the prolonged disruption to Middle Eastern supply, pushing US crude exports to 4.75 million barrels per day.Volatility surged again by Thursday after reports emerged of Iranian missiles targeting US Navy vessels and explosions near Bandar Abbas.The escalation followed a US Treasury move to sanction Iraq's deputy oil minister for allegedly helping Iran bypass embargoes.While these flashes of conflict forced prices higher in the final sessions, they were insufficient to erase the cumulative losses of a week defined by the market's search for a diplomatic floor.Saxo analysts added that the International Energy Agency has pegged regional supply losses at about 14 million barrels per day, "only partly offset by surging US exports, strategic reserve releases and demand destruction."Weekly US oil product exports hit a record high, according to EIA data.US exports of total petroleum products hit a record 8.2 mmb/d in the week ending May 1, the highest level since the Energy Information Administration started reporting the product export data in February 1991.The weekly figure is up from 7.7 mmb/d a week ago, according to the EIA.Total weekly US crude oil and petroleum products exports stood at 12.97 mmb/d, down from 14.18 mmb/d a week prior, driven by a sharp drop in crude exports, EIA data showed.Weekly crude exports were at 4.8 mmb/d, down from 6.4 mmb/d the previous week.Meanwhile, the US oil rig count rose by two from 408 the previous week to 410 in the week ending May 8, according to data from Baker Hughes (BKR) released Friday. That compares with 467 oil rigs in operation a year earlier.The consolidated North American oil and gas rig count, a key early indicator of future production levels, rose by two to 672 from 670 the previous week.Money managers in the WTI crude futures and options markets maintained their net long positions in the week ended May 5, according to the Commodity Futures Trading Commission's latest Commitments of Traders report released on Friday.The data showed that money managers reported 214,039 long positions, down 5,611 from April 28, while short positions were down 2,066 to 82,083.

$BKR
Research

Research Alert: CFRA Lifts Opinion On Shares Of Expedia Group To Hold From Sell

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $12 to $252, representing 13x our 2026 EPS estimate (unchanged multiple), a discount to EXPE's 21x five-year average forward multiple justified by consumer spending and competitive risks. We raise our 2026 EPS estimate to $19.41 from $18.51 and 2027's to $22.18 from $20.38. Our higher revised estimates reflect resilient Q1 gross bookings growth (+13% Y/Y) despite volatile trends in response to the conflict in Iran. Management reiterated its 2026 gross bookings outlook of 6%-8%, which appears conservative given potential benefits to travel brought by the World Cup in North America. The company also saw significant leverage over sales and marketing (-400 bps Y/Y). If EXPE were to achieve its gross bookings guidance and sustain operating leverage, we see a reasonable path to achieve low-double-digit EPS growth in 2026. We view shares trading below their five-year average offering a more balanced risk/reward. Thus, we lift our opinion to Hold from Sell.

$EXPE
Research

Research Alert: We Keep Our Buy Rating On Shares Of Gilead Sciences, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $170 on a multiple of 17.0x our 2027 EPS estimate, above GILD's five-year historical forward P/E average of 10.2x, justified by its improving outlook, in our view. We adjust our 2026 view to a loss of 0.67 per share from an EPS of $8.79 to account for the acquired IPR&D charges related to the Arcellx, Ouro, and Tubulis transactions. We lower our 2027 EPS estimate to $9.98 from $10.19. GILD reported a strong Q1 2026, above expectations for both revenue and EPS. Total product sales rose 5% Y/Y to $6.9B, while sales excluding Veklury (Covid-19 treatment) grew 8% to $6.8B. This performance was supported by robust growth in the HIV franchise, particularly the exceptional launch of the PrEP drug Yeztugo, and strong sales from the oncology drug Trodelvy. We think GILD is making solid progress in its pipeline, which management describes as the strongest in its history, bolstered by the recent acquisitions of Arcellx and the pending acquisitions of Ouro Medicines and Tubulis.

$GILD